Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy

Oncology

Volumn 25, Issue 8, 2011, Pages 1-4

  Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; CYTARABINE; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; RETINOIC ACID;

ARTICLE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; HIGH RISK PATIENT; HUMAN; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMYELOCYTIC LEUKEMIA;

EID: 79961232438     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Park JH, Tallman MS. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park). 2011;25:XXXX-XXXX.
2. Avvisati G, Petti MC, Lo Coco F, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study lap 0389 with 7 years of minimal follow-up. Blood. 2002;100:3141-6.
3. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-72.
4. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-60.
5. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-32.
6. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without atra and/or chemotherapy. Ann Oncol. 2006;17:131-34.
7. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28:3866-71.
8. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; June 6 [Epub ahead of print].
9. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American leukemia intergroup study c9710. Blood. 2010;116:3751-7.
10. Ades L, Raffoux E, Chevret S, et al. Arsenic trioxide (ATO) in the consolidation treatment of newly diagnosed APL - first interim analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group (abstract). Blood. 2010;116:505.
11. Jing Y, Wang L, Xia L, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001;97:264-9.
12. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/as2o3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:5328-35.
13. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106:3342-47.
14. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504-10.
15. Ravandi F, Estey EH, Cortes JE, et al. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL)(abstract). Blood. 2010;116:1080.
16. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650-8.
17. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011; Jun 8 [Epub ahead of print]
18. Micol J-B, Raffoux E, Boissel N, et al. Do early events excluding patients with acute promyelocytic leukemia (APL) from trial enrollment modify treatment result evaluation? Real-life management of 100 patients referred to the university Hospital Saint-Louis between 2000 and 2010 (abstract). Blood 2010;116:1083.
19. Dimov ND, Medeiros LJ, Kantarjian HM, et al. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer. 2010;116:369-76.